Vanguard Group Inc. Sells 1,383,039 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Vanguard Group Inc. reduced its stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 31.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,985,952 shares of the biotechnology company's stock after selling 1,383,039 shares during the period. Vanguard Group Inc. owned 6.03% of REGENXBIO worth $23,081,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Barclays PLC raised its holdings in REGENXBIO by 141.3% in the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock worth $1,217,000 after purchasing an additional 67,948 shares during the period. Assenagon Asset Management S.A. lifted its stake in REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after buying an additional 296,700 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of REGENXBIO by 602.9% in the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company's stock valued at $214,000 after buying an additional 17,533 shares during the period. FMR LLC increased its position in shares of REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 1,656 shares in the last quarter. Finally, Stifel Financial Corp raised its holdings in shares of REGENXBIO by 13.3% during the third quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company's stock worth $1,566,000 after acquiring an additional 17,563 shares during the period. 88.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RGNX has been the topic of several recent research reports. Chardan Capital reissued a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Thursday, March 20th. The Goldman Sachs Group cut their target price on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday. StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. Finally, Morgan Stanley increased their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.63.

REGENXBIO Trading Down 3.6 %

Shares of REGENXBIO stock traded down $0.22 during trading on Friday, hitting $5.94. 649,002 shares of the stock were exchanged, compared to its average volume of 800,635. REGENXBIO Inc. has a 1-year low of $5.04 and a 1-year high of $17.52. The stock has a market capitalization of $297.69 million, a price-to-earnings ratio of -1.18 and a beta of 1.26. The company has a fifty day moving average price of $6.84 and a 200-day moving average price of $8.18.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The company had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. Equities research analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.